These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35089680)

  • 1. Adjuvant combined therapy with trastuzumab in patients with HER2‑ positive breast cancer and cardiac alterations: implications for optimal cardio‑oncology care.
    Grela-Wojewoda A; Niemiec J; Sas-Korczyńska B; Zemełka T; Puskulluoglu M; Wysocki WM; Wojewoda T; Pacholczak-Madej R; Adamczyk A; Mucha-Małecka A; Ziobro M; Konduracka E
    Pol Arch Intern Med; 2022 Apr; 132(4):. PubMed ID: 35089680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
    JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
    de Azambuja E; Agostinetto E; Procter M; Eiger D; Pondé N; Guillaume S; Parlier D; Lambertini M; Desmet A; Caballero C; Aguila C; Jerusalem G; Walshe JM; Frank E; Bines J; Loibl S; Piccart-Gebhart M; Ewer MS; Dent S; Plummer C; Suter T;
    ESMO Open; 2023 Feb; 8(1):100772. PubMed ID: 36681013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.
    Glen C; Morrow A; Roditi G; Hopkins T; Macpherson I; Stewart P; Petrie MC; Berry C; Epstein F; Lang NN; Mangion K
    Heart; 2024 Apr; 110(9):650-656. PubMed ID: 38103912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer.
    Peddi PF; Fasching PA; Liu D; Quinaux E; Robert NJ; Valero V; Crown J; Falkson C; Brufsky A; Cunningham JM; Weinshilboum RM; Pienkowski T; Eiermann W; Martín M; Bee V; Wang X; Wang L; Yang E; Slamon DJ; Hurvitz SA
    Clin Cancer Res; 2022 May; 28(9):1854-1862. PubMed ID: 35110416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
    Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab.
    Canale ML; Casolo G; Donati S; Bisceglia I; Puccetti C; Amoroso D; Venturini E; Maurea N; Turazza FM; Camerini A
    In Vivo; 2023; 37(5):2139-2146. PubMed ID: 37652487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
    Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
    Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
    Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
    Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
    Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.